SAT0264 Efficacy and Safety of TOCILIZUMAB in Elderly Patients with Rheumatoid Arthritis

Objectives To assess safety and efficacy of tocilizumab (TCZ) in elderly (≥65 years) rheumatoid arthritis (RA) patients treated in daily practice. Methods We conducted a retrospective study of TCZ use in RA patients followed in five French university hospitals from 2009 to 2012. We considered two age groups ( A multivariate cumulative logit model for ordinal categories was performed to assess the relationship between age class and EULAR response (none, moderate and good) adjusted on possible confounders. TCZ retention (drug survival) over time was estimated with the Kaplan-Meier method. Treatment retention curves were compared according to age group with the log-rank test. Results Among 222 RA patients treated by TCZ, 61 (27.5%) were ≥65 years at therapy initiation. After 6 months, elderly patients less often reached remission (27.8% versus 45.6%; p=0.02) or good EULAR response (40.7% versus 61.0%; p Conclusions In daily practice, TCZ seems well tolerated but less efficient in elderly RA patients. Broader analyses like international register are now needed to confirm our results. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1513